By Fineline Cube 
China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, sponsored solely by SDIC Securities. Founded in 2002 as an innovation-driven biopharmaceutical company, Hemay Pharma specializes in the research and development of innovative small-molecule drugs targeting autoimmune diseases and oncology.
Innovative Pipeline and Clinical Progress
Hemay Pharma’s pipeline comprises seven drug candidates, with four currently at Phase II/III or New Drug Application (NDA) stages, covering 12 indications. The company’s lead candidate, mufemilast, a novel small-molecule targeted drug with dual mechanisms as a PDE4B protein expression blocker and PDE4 inhibitor, is under priority review in China. It has completed a Phase III study in psoriasis (Ps) within the country. Additionally, Hemay022, an EGFR/HER2 dual inhibitor, is undergoing a Phase III study for advanced ER+/HER2+ breast cancer.
Financial Performance
In 2024, Hemay Pharma reported revenues of RMB 5.3 million (USD 736,938) and a loss of RMB 123 million (USD 17 million), reflecting its continued investment in research and development to advance its promising drug candidates.-Fineline Info & Tech